Azithromycin Suspension Solicitation
ID: SPE2D2-25-R-0001Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/0dce91d05ea248cb9de975061471eb5d/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Azithromycin Suspension, as outlined in Solicitation No. SPE2D2-25-R-0001. This Request for Proposal (RFP) seeks various formulations of Azithromycin, emphasizing compliance with federal regulations, including the Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS), to ensure the integrity and quality of pharmaceutical supplies. The procurement is critical for maintaining a reliable supply of essential drugs for military and defense operations. Interested vendors must submit their offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between October 29 and December 2, 2024. For further inquiries, vendors can contact Kahaun Vicks at Kahaun.Vicks@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.

    Point(s) of Contact
    Kahaun Vicks
    (215) 737-0652
    Kahaun.Vicks@dla.mil
    Jason C. Wray
    (215) 737-0614
    Jason.Wray@dla.mil
    Files
    Title
    Posted
    Azithromycin Suspension Solicitation.pdf
    The document details Solicitation No. SPE2D2-25-R-0001, issued by the Defense Logistics Agency, outlining a Request for Proposal (RFP) for pharmaceutical products, specifically various formulations of Azithromycin. The RFP includes critical contractual clauses under the Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS), emphasizing compliance, subcontracting plans for large businesses, ethics code, and contractor performance assessments. Vendors are instructed to submit offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between October 29 and December 2, 2024. The document specifies estimated quantities for the pharmaceuticals and mandates adherence to multiple legal provisions regarding production, subcontracting, and business practices. Through this solicitation, the DLA seeks to ensure the procurement of essential drugs while promoting fair competition and compliance with federal regulations. The thoroughness of the contract provisions ensures that contractors maintain integrity in governmental dealings and meet quality standards in pharmaceutical supplies.
    SPE2D225R00010001_Sol extended to 18.Dec.2024.pdf
    The document consists of fragmented and corrupted content that appears to reference various topics related to federal and state RFPs (Requests for Proposals) and grant opportunities. Key themes include the processes surrounding the submission of proposals and the regulatory compliance required in government contracting. There are mentions of fiscal constraints, program evaluations, and the importance of meeting project specifications for grant funding. While it is difficult to ascertain the complete structure due to the fragmented nature, the text suggests a focus on compliance, assessment protocols, and potential environmental concerns during project execution. The document might aim to guide stakeholders in understanding requirements for pursuing federal or state projects, emphasizing collaborations and adherence to regulatory frameworks. Overall, the material indicates a need for thorough understanding and careful navigation of governmental processes in RFPs and grant applications.
    Lifecycle
    Title
    Type
    Azithromycin Suspension
    Presolicitation
    Azithromycin Suspension Solicitation
    Currently viewing
    Solicitation
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Lamotrigine
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of various dosages of Lamotrigine ER, a pharmaceutical product. This solicitation (SPE2D2-25-R-0002) outlines the submission procedures for interested contractors, emphasizing the requirement for electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of January 9, 2025. Lamotrigine is a critical medication used in the treatment of epilepsy and bipolar disorder, making this procurement essential for maintaining adequate supplies for military and healthcare facilities. For further inquiries, interested parties can contact Nancy Fernandez at nancy.fernandez@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Doxycycline Hyclate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Rizatriptan Benzoate
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotations for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of its pharmacy benefits program for the Military Health System (MHS). This procurement aims to establish Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADPs) for cost-effective pharmaceutical options, ensuring that the selected agents meet clinical and cost-effectiveness criteria as evaluated by the Pharmacy and Therapeutics (P&T) Committee. The initiative is critical for providing safe and effective medications to military beneficiaries while managing costs within the healthcare system. Interested manufacturers must submit their quotes by December 30, 2024, and can direct inquiries to Tracy Banks or Keith Marasigan via their respective emails for further information.
    65--DANTROLENE SODIUM F
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking quotes for the procurement of Dantrolene Sodium F, a critical medical supply. The solicitation includes multiple line items, each requiring a quantity of three units to be delivered to the W05J Medical Maintenance Operations Division at Tobyhanna, with a delivery timeline of five days after order. Dantrolene Sodium is essential for treating malignant hyperthermia and is vital for patient safety in medical settings. Interested vendors must submit their quotes electronically, and any inquiries regarding the solicitation should be directed to the buyer via email at DibbsBSM@dla.mil.